Hemogenyx Pharmaceuticals is a biopharmaceutical company based in London that works on cell and gene therapies for blood cancers and other serious diseases. Its research includes engineered immune cell treatments aimed at acute myeloid leukaemia and other conditions, along with specialised laboratory models used to study how human blood and immune systems respond to potential medicines. The company carries out early-stage laboratory and preclinical development, working with academic and clinical collaborators to advance its programmes toward testing in patients.
Hemogenyx Pharmaceuticals PLC trades under the code HEMO on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Weak price profile
Ranks #3084 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendWeak
20/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-7.6%
From 52-week high-39.1%
MomentumWeak
33/100
Lagging most stocks on this exchange.
See the numbers →
3-month return3.2%
6-month return-11.3%
12-month, skipping last month-49.4%
Stability (higher is calmer)Weak
9/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)97.9%
Worst drawdown, 1 year (smaller is calmer)-61.8%
LiquidityStrong
76/100
Trades actively.
See the numbers →
Avg daily value traded13.26M GBX
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 356.00 – 1,220.00Daily closes, split-adjusted
Signals
50-day average573.90
200-day average754.75
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)83.66
Technical summary
Daily
Bullish
10 bullish · 4 neutral · 2 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 2 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
SMA 10
703.5
Bearish
EMA 10
690.4
Bullish
SMA 20
651.8
Bullish
EMA 20
654.6
Bullish
SMA 50
573.9
Bullish
EMA 50
620.8
Bullish
SMA 100
655.8
Bullish
EMA 100
648.0
Bullish
SMA 200
754.7
Bearish
EMA 200
678.6
Bullish
Oscillators (daily)
RSI (14)
57.12
Neutral
MACD (12, 26)
44.21
Bullish
Momentum (12)
12.68
Bullish
Stochastic %K (14)
48.99
Neutral
Williams %R (14)
-51.01
Neutral
CCI (20)
48.36
Neutral
Pivot points (classic, last session)
S3
583.3
S2
619.2
S1
658.3
Pivot
694.2
R1
733.3
R2
769.2
R3
808.3
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in GBX. Educational only, not financial advice.
